Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL698803 | 0.91 | USP2 (0.69) | USP2SMN1; SMN2HPGDEPHX2GPR119 | |
| SCHEMBL18294 | 0.91 | USP2 (0.69) | USP2SMN1; SMN2HPGDEPHX2GPR119 | |
| SCHEMBL26134029 | 0.89 | USP2 (0.50) | USP2SMN1; SMN2HPGDEPHX2GPR119 | |
| SCHEMBL31505417 | 0.88 | MAPT (0.49) | USP2SMN1; SMN2HPGDEPHX2GPR119 | |
| SCHEMBL31505486 | 0.88 | USP2 (0.49) | USP2SMN1; SMN2HPGDEPHX2GPR119 | |
| SCHEMBL31505455 | 0.87 | USP2 (0.51) | USP2SMN1; SMN2HPGDEPHX2GPR119 | |
| SCHEMBL8661760 | 0.87 | GPR119 (0.64) | USP2SMN1; SMN2HPGDGPR119RECQL | |
| SCHEMBL18642349 | 0.85 | USP2 (0.58) | USP2SMN1; SMN2HPGDEPHX2GPR119 | |
| SCHEMBL4474239 | 0.85 | HPGD (0.50) | USP2SMN1; SMN2HPGDGPR119RECQL | |
| SCHEMBL20816238 | 0.85 | USP2 (0.46) | USP2SMN1; SMN2HPGDEPHX2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4448107-B1 | DRUG DELIVERY SYSTEMS BASED ON ENDOPEROXIDES USEFUL IN DIAGNOSIS AND THERAPY, AND METHODS THEREOF | FACULDADE DE FARMACIA DA UNIV DE LISBOA (PT) | 2025-11-05 | — | — | EP | claimed |
| US-20250064840-A1 | DRUG DELIVERY SYSTEMS BASED ON ENDOPEROXIDES USEFUL IN DIAGNOSIS AND THERAPY, AND METHODS THEREOF | FACULDADE DE FARMÁCIA DA UNIVERSIDADE DE LISBOA (PT) | 2025-02-27 | — | — | US | claimed |
| EP-4448107-A1 | DRUG DELIVERY SYSTEMS BASED ON ENDOPEROXIDES USEFUL IN DIAGNOSIS AND THERAPY, AND METHODS THEREOF | Faculdade de Farmácia da Universidade de Lisboa (PT) | 2024-10-23 | — | — | EP | claimed |
| WO-2023111829-A1 | DRUG DELIVERY SYSTEMS BASED ON ENDOPEROXIDES USEFUL IN DIAGNOSIS AND THERAPY, AND METHODS THEREOF | FACULDADE DE FARMÁCIA DA UNIVERSIDADE DE LISBOA (PT) | 2023-06-22 | — | — | WO | claimed |
| EP-0998459-B1 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2008-04-23 | — | — | EP | claimed |
| US-20070265279-A1 | Use of mGluR5 antagonists for the treatment of pruritic conditions | NOVARTIS AG (CH) | 2007-11-15 | — | — | US | claimed |
| EP-1359905-B1 | USE OF MGLUR5 ANTAGONISTS FOR THE TREATMENT OF PRURITIC CONDITIONS | NOVARTIS AG (CH) | 2006-07-26 | — | — | EP | claimed |
| US-20040142999-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2004-07-22 | — | — | US | claimed |
| EP-1397340-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-03-17 | — | — | EP | claimed |
| WO-2002098850-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-12-12 | — | — | WO | claimed |
| EP-4448107-B1 | DRUG DELIVERY SYSTEMS BASED ON ENDOPEROXIDES USEFUL IN DIAGNOSIS AND THERAPY, AND METHODS THEREOF | FACULDADE DE FARMACIA DA UNIV DE LISBOA (PT) | 2025-11-05 | — | — | EP | disclosed |
| CN-119855586-A | Compositions and methods for treating metabolic disorders | 加利福尼亚大学董事会 | 2025-04-18 | — | — | CN | disclosed |
| CN-119613483-A | Degradation agent for targeting BET and/or CBP/p300 protein and application thereof | 国科宁波生命与健康产业研究院 | 2025-03-14 | — | — | CN | disclosed |
| CN-115894439-B | PROTAC chimeric capable of degrading GPX4 in targeted manner, and preparation method and application thereof | 中国科学院基础医学与肿瘤研究所(筹) | 2024-12-17 | — | — | CN | disclosed |
| CN-117897386-A | Benzopyran derivatives and uses thereof | 斯帕克生物制药有限公司 | 2024-04-16 | — | — | CN | disclosed |
| EP-1397340-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-03-17 | — | — | EP | disclosed |
| EP-1392363-A2 | COMPOSITIONS AND USES OF MGLUR5 ANTAGONISTS | BROWN UNIVERSITY RESEARCH FOUNDATION (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20030100539-A1 | Methods of treating neurological disorders with group I mGluR antagonists | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-05-29 | — | — | US | disclosed |
| WO-2002098850-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-12-12 | — | — | WO | disclosed |
| WO-2002078745-A2 | USE OF MGLUR5 ANTAGONISTS IN THE MANUFACTURE OF A MEDICAMENT IN THE TREATMENT OF AUTISM, MENTAL RETARDATION, SCHIZOPHRENIA | BROWN UNIVERSITY RESEARCH FOUNDATION (US) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265279-A1 | Use of mGluR5 antagonists for the treatment of pruritic conditions | GRM5, GRIK5, MRGPRX2 | USP2 3018/4885SMN1; SMN2 2238/4885HPGD 1861/4885 |
| US-20030100539-A1 | Methods of treating neurological disorders with group I mGluR antagonists | GRM5, GRIK5, GRIN1 | USP2 3155/4885SMN1; SMN2 102/4885HPGD 1469/4885 |
| US-20250064840-A1 | DRUG DELIVERY SYSTEMS BASED ON ENDOPEROXIDES USEFUL IN DIAGNOSIS AND THERAPY, AND METHODS THEREOF | FECH, PTGIS, EPHX1 | USP2 3350/4885SMN1; SMN2 3826/4885HPGD 379/4885 |
| US-20040142999-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | USP2 516/4885SMN1; SMN2 3350/4885HPGD 1645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.